for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Lupin Limited

LUPN.NS

Latest Trade

735.35INR

Change

-3.00(-0.41%)

Volume

191,127

Today's Range

734.00

 - 

742.80

52 Week Range

646.30

 - 

906.00

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
738.35
Open
739.85
Volume
191,127
3M AVG Volume
27.95
Today's High
742.80
Today's Low
734.00
52 Week High
906.00
52 Week Low
646.30
Shares Out (MIL)
452.73
Market Cap (MIL)
330,654.80
Forward P/E
29.48
Dividend (Yield %)
0.68

Next Event

Q3 2020 Lupin Ltd Earnings Release

Latest Developments

More

Lupin To Sell Entire Stake In Kyowa Pharmaceutical Industry

India's Lupin Posts Sept Quarter Consol Net Loss

Lupin Gets FDA Approval For Divalproex Sodium ER Tablets

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Lupin Limited

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central nervous system, gastro-intestinal, anti-infectives and non-steroidal anti-inflammatory drug therapy areas. The Company also offers solutions in the anti-tuberculosis (anti-TB) and cephalosporins therapy areas. The Company along with its subsidiaries has manufacturing locations spread across India, Japan, the United States, Mexico and Brazil. It has a pipeline of biosimilars addressing therapies, such as oncology, anti-inflammatory, anti-viral, rheumatoid arthritis, endocrinology, diabetes, ophthalmology and women's health. The Company's products include Antara, Methergine, Methylphenidate, Glumetza, Gluconorm, Tonact, Rcinex and Ramistar, among others.

Industry

Biotechnology & Drugs

Contact Info

B/4 Laxmi Towers

, Bandra Kurla Complex, Bandra (E)

+91.22.66402222

http://www.lupin.com/

Executive Leadership

Manju Deshbandhu Gupta

Chairman of the Board

Vinita D. Gupta

Chief Executive Officer, Executive Director

Kamal K. Sharma

Non-Executive Vice Chairman of the Board

Sunil Makharia

Interim Chief Financial Officer

Debabrata Chakravorty

President – Global Sourcing & Contract Manufacturing

Key Stats

3.10 mean rating - 40 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

171.2K

2018

155.6K

2019

163.7K

2020(E)

175.9K
EPS (INR)

2017

56.460

2018

30.730

2019

20.840

2020(E)

24.879
Price To Earnings (TTM)
105.49
Price To Sales (TTM)
1.87
Price To Book (MRQ)
2.43
Price To Cash Flow (TTM)
21.72
Total Debt To Equity (MRQ)
63.67
LT Debt To Equity (MRQ)
48.83
Return on Investment (TTM)
1.48
Return on Equity (TTM)
1.13

Latest News

Latest News

UPDATE 1-India's Lupin posts Q3 loss on charge related to blood pressure drug

Indian drugmaker Lupin Ltd posted a surprise quarterly loss on Wednesday after taking a one-time charge related to litigation over a blood pressure drug.

India's Lupin posts quarterly loss on one-off charge

Indian drugmaker Lupin Ltd posted a surprise third-quarter loss on Wednesday, due to a one-off charge in the quarter.

UPDATE 1-India's Lupin Q2 profit dives as U.S. sales, higher expenses weigh

Lupin Ltd, India's second-largest drugmaker by revenue, posted a lower-than-expected second-quarter profit on Wednesday, as sales in the United States - a key market - dropped and overall manufacturing costs rose.

India's Lupin Q2 profit falls, misses estimates

Lupin Ltd, India's second-largest drugmaker by revenue, posted a 41.5 percent fall in second-quarter profit on Wednesday, hurt by higher expenses.

UPDATE 1-India's Lupin Q1 profit misses estimate by wide margin

Drugmaker Lupin Ltd posted a bigger-than-expected fall in first-quarter profit on Wednesday, hurt by declining sales in the United States and Japan.

India's Lupin quarterly profit falls 43 pct

Drugmaker Lupin Ltd posted a 43 percent fall in first-quarter profit on Wednesday, widely missing analysts' estimates.

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING

UPDATE 2-India's Lupin expects U.S. drug pricing pressure to ease in 2019

* U.S. sales fall 21.1 pct; India sales up 14 pct (Adds management comments from conference call)

India's Lupin posts surprise Q4 loss on one-time charge

Lupin Ltd, India's second-largest drugmaker by revenue, reported a surprise loss in its fiscal fourth quarter on Tuesday, due to a one-time charge.

BRIEF-India's Lupin Gets FDA Approval For Generic Temovate Ointment, 0.05 Percent

* GETS FDA APPROVAL FOR GENERIC TEMOVATE OINTMENT, 0.05 PERCENT

BRIEF-India's Lupin Gets FDA Nod For Generic Xenazine Tablets, 12.5 Mg And 25 Mg

* SAYS CO RECEIVES FDA APPROVAL FOR GENERIC XENAZINE TABLETS, 12.5 MG AND 25 MG Source text - http://bit.ly/2qUd2T4 Further company coverage:

BRIEF-India's Lupin Gets Tentative U.S. FDA Nod For Generic Androgel, 1.62 Pct

* SAYS CO RECEIVES TENTATIVE FDA APPROVAL FOR GENERIC ANDROGEL, 1.62 PERCENT Source text - https://bit.ly/2HEhHk8 Further company coverage:

BRIEF-Lupin's Pithampur Unit 1 Facility Gets EIR From U.S. FDA

* SAYS PITHAMPUR UNIT 1 FACILITY RECEIVES ESTABLISHMENT INVESTIGATION REPORT (EIR) FROM US FDA

BRIEF-Lupin's Goa Facility Completes Successful U.K MHRA Inspection

* SAYS CO'S GOA FACILITY COMPLETES SUCCESSFUL UK MHRA INSPECTION

BRIEF-India's Lupin Says Pithampur Unit Cleared By Health Canada

* SAYS HEALTH CANADA MAINTAINED COMPLIANT RATING FOR UNIT 2 AT PITHAMPUR (INDORE) AND HAS ISSUED A REVISED ‘ESTABLISHMENT LICENSE’ Source text - https://bit.ly/2pW8cVF Further company coverage:

BRIEF-Lupin Launches Generic Clobex Spray, 0.05 Pct In U.S.

* SPRAY IS USED FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS AFFECTING UP TO 20 PERCENT BODY SURFACE AREA IN PATIENTS 18 YEARS OF AGE OR OLDER Source text: http://bit.ly/2IeyRDQ Further company coverage:

BRIEF-India's Lupin Gets FDA Nod For Generic Clobexa Spray, 0.05 Pct

* SAYS CO GETS FDA APPROVAL FOR GENERIC CLOBEXA SPRAY, 0.05% Source text - https://bit.ly/2Gg8Sf1 Further company coverage:

BRIEF-Lupin Launches Generic Lodosyn Tablets In The U.S.

* SAYS LUPIN LAUNCHES GENERIC LODOSYN TABLETS IN THE US Source text: https://bit.ly/2I72Ldw Further company coverage:

BRIEF-Lupin Gets FDA Approval For Generic Topicort Topical Spray, 0.25 Pct

* SAYS CO RECEIVES FDA APPROVAL FOR GENERIC TOPICORT TOPICAL SPRAY, 0.25 PERCENT Source text - http://bit.ly/2DEhb1S Further company coverage:

BRIEF-Lupin Launches Tydem Tablets

* SAYS LAUNCH OF TYDEM TABLETS Source text: http://bit.ly/2FMGgNe Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up